The challenge of institutionalised complicity: Researching the pharmaceutical industry in the era of impact and engagement

Martin, Paul

doi:10.1111/1467-9566.13536

Cited by 5 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complicity might involve lending legitimacy to industry agenda, failing to call out or question unacceptable practices, ignoring the experience of patients and marginalized groups, adopting the norms and values of the dominant actor that wants to avoid scrutiny. Direct suppression or deliberate non-engagement may occur in order to make research the servant of economic prosperity ( 77 ). Industry does not have a good record of engagement with SDOH and environmental impacts on health, consistently and across many industries, protecting their products and asserting individual choice is the only necessary protection.…”

Section: Relationship Of Conflict Of Interest With Related Constructs...mentioning

confidence: 99%

Rebalancing commercial and public interests in prioritizing biomedical, social and environmental aspects of health through defining and managing conflicts of interest

Redman

2023

Front. Med.

View full text Add to dashboard Cite

Biomedical research is intended to benefit human beings and their health. Toward that end, scientific norms involve examining and criticizing the work of others and prioritizing questions that should be studied. Yet, in areas of health research where industry is active, it has often utilized well-honed strategies aimed at evading scientific standards and at dominating the research agenda, largely through its financial support and lack of transparency of its research practices. These tactics have now been documented to uniformly support industry products. Commercial entities are aided in this pursuit by public policy that has significantly embedded commercial interests and agendas into federal research funding and infrastructure. Therefore, to understand the resulting landscape and its effect on priority in health research agendas, traditional definitions of individual conflicts of interest (COI) and the less well developed institutional COI must be supplemented by a new construct of structural COI, largely operating as intellectual monopolies, in support of industry. These arrangements often result in financial and reputational resources that assure dominance of commercial priorities in research agendas, crowding out any other interests and ignoring justified returns to the public from investment of its tax dollars. There is no sustained attention to mechanisms by which public interests can be heard, normative issues raised, and then balanced with commercial interests which are transparently reported. Focus on research supporting approval of commercial products ignores social and environmental determinants of health. Commercial bias can invalidate regulatory research protections through obscuring valid risk–benefit ratios considered by IRBs.

show abstract

Section: Relationship Of Conflict Of Interest With Related Constructs...mentioning

confidence: 99%

Rebalancing commercial and public interests in prioritizing biomedical, social and environmental aspects of health through defining and managing conflicts of interest

Redman

2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…All of the papers here, including this introduction, are, of course, steeped in their institutional context. Nonetheless, the final two papers in this collection particularly foreground the possibility of institutional complicity, with Martin’s (2022) contribution devoting particular attention to funding bodies. Martin discusses applying for a grant from The Wellcome Trust wherein he hoped to study ‘high‐priced drugs for rare diseases’ (p. 159).…”

Section: The Papersmentioning

confidence: 99%

Complicity: Methodologies of power, politics and the ethics of knowledge production

Hollin

Williams

2022

Sociology Health & Illness

View full text Add to dashboard Cite

In this collection we develop the concept of “complicity” as a means to understand how medical sociologists might be allied in unexpected or uncomfortable ways with dominant structures of power. After giving examples of complicity from our own research, we introduce existing scholarship on complicity, describing it as a concept that comes coupled with a sense of responsibility and that is related to, yet distinct from, a range of other terms including reflexivity, collusion, guilt, and shame. We also discuss how complicity has been described to occur at the level of the institution, within theoretical frameworks, and during mundane moments that we face on a day‐to‐day basis. Building on this review, we hypothesise that medical sociology – where access to fieldsites is often hard won, where “researching up” in medical and scientific institutions is common, and where our own work frequently concerns matters central to medical institutions themselves – is a discipline wherein mundane complicity is likely. Following this gathering exercise, we introduce the interventions that comprise this collection: interventions from a diversity of sociologists of health and illness who, perhaps for the first time in written form, account for how complicities of various kinds came to shape their work and how, with varying levels of success, they have sought redress. We close by offering some insight into the process of developing this collection, celebrating its successes while also acknowledging that many gaps and complicities remain.

show abstract

Together for the greater goods: legitimising social innovation in the pharmaceutical field

Kleinhout-Vliek,

Boon,

Hagendijk

et al. 2024

Innovation: The European Journal of Social Science Research

View full text Add to dashboard Cite

The challenge of institutionalised complicity: Researching the pharmaceutical industry in the era of impact and engagement

Abstract: This is a repository copy of The challenge of institutionalised complicity: researching the pharmaceutical industry in the era of impact and engagement.

Cited by 5 publications

References 50 publications

Rebalancing commercial and public interests in prioritizing biomedical, social and environmental aspects of health through defining and managing conflicts of interest

Rebalancing commercial and public interests in prioritizing biomedical, social and environmental aspects of health through defining and managing conflicts of interest

Complicity: Methodologies of power, politics and the ethics of knowledge production

Together for the greater goods: legitimising social innovation in the pharmaceutical field

Contact Info

Product

Resources

About